• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Galderma approved for Differin(R) Gel 0.1 percent in Japan

Lausanne, Switzerland - Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).

Lausanne, Switzerland

- Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).

The drug, used to treat acne vulgaris, will be marketed in Japan by Galderma KK, the Japanese arm of Galderma.

Related Videos
3 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.